LUCD Lucid Diagnostics Total Debt to Capital

Scaling the distribution of EsoGuard rapid diagnostics for the detection of precancerous esophageal pathologies is delivering tangible results, although insurance mechanisms are still being refined. Lucid Diagnostics Inc. (LUCD) is acting as a pioneer in the precision risk analysis of gastrointestinal oncology by investing in AI technologies and DNA markers. The market dynamics of the asset with the 2.14 indicator illustrate the brand's path toward establishing a global standard for non-invasive cancer prevention.

The ratio is calculated as total liabilities divided by net shareholders' equity. This metric determines the degree of financial leverage and the level of business dependence on external borrowing. For Lucid Diagnostics Inc. (LUCD), the debt balance is critical when scaling express logistics and laboratory infrastructure. Controlling the share of all liabilities relative to equity confirms the stability of the operating model. The dynamics of this ratio reflect the actual bankruptcy risk.